Sovremennye dostizheniya v lekarstvennoy terapii disseminirovannoy melanomy kozhi


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Over the last 5 years due to the introduction of modern high-effective drugs into clinical practice, the effectiveness of the treatment of disseminated melanoma has improved significantly. Preclinical studies have demonstrated the possibility of using antibodies blocking the PD-1 or PD-L1 for the treatment of various tumors. Antitumor activity was demonstrated in melanoma, kidney cancer, bladder cancer, lung cancer and some other cancers. Based on the published results of the key clinical trials, such as KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006, pembrolizumab was recommended as a high-effective drug for the treatment of disseminated skin melanoma.

Full Text

Restricted Access

About the authors

M. E Abramov

References

  1. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R., Buzaid A.C., Cochran A.J., Coit D.G., Ding S., Eggermont A.M., Flaherty K.T., Gimotty P.A., Kirkwood J.M., McMasters K.M., Mihm M.C. Jr, Morton D.L., Ross M.I., Sober A.J., Sondak V.K Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 2009;27: 6199-206.
  2. Hauschild A. Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations. Curr. Oncol. 2009;16:3-6.
  3. Ballantyne A.D., Garnock-Jones K.P. Dabrafenib: first global approval. Drugs. 2013;73:1367-76.
  4. Bollag G., Tsai J., Zhang J., Zhang C., Ibrahim P., Nolop K., Hirth P. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat. Rev. Drug. Discov. 2012;11:873-86.
  5. Wright C.J., McCormack P.L. Trametinib: first global approval. Drugs. 2013;73:1245-54.
  6. Sznol M. Advances in the treatment of metastatic melanoma: new immunomodulatory agents. Semin. Oncol. 2012;39:192-203
  7. Blank C., Brown I., Peterson A.C., Spiotto M., Iwai Y., Honjo T., Gajewski T.F. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004;64:1140-45.
  8. Okazaki T., Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 2007;19:813-24.
  9. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., KeffordR., WolchokJ.D., HerseyP., Joseph R.W., Weber J.S., Dronca R., Gangadhar T.C., Patnaik A., Zarour H., Joshua A.M., Gergich K., Elassaiss-Schaap J., Algazi A., Mateus C., Boasberg P., Tumeh P.C., Chmielowski B., Ebbinghaus S.W., Li X.N., Kang S.P., Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 2013;369:134-44.
  10. Robert C., Ribas A., Wolchock J.D., Hodi F.S., Hamid O., Kefford R., Weber J.S., Joshua A.M., Hwu W.J., Gangadhar T.C., PatnaikA., Dronca R., Zarour H., Joseph R.W., Boasberg P., Chmielowski B., Mateus C., Postow M.A., Gergich K., Elassaiss-Schaap J., Li X.N., Iannone R., Ebbinghaus S.W., Kang S.P., Daud A. Anti-programmed-deathreceptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109-17.
  11. Herbst R.S., Soria J.C., Kowanetz M., Fine G.D., Hamid O., Gordon M.S., Sosman J.A., McDermott D.F., Powderly J.D., Gettinger S.N., Kohrt H.E., Horn L., Lawrence D.P., Rost S., Leabman M., Xiao Y., Mokatrin A., Koeppen H., Hegde P.S., Mellman I., Chen D.S., Hodi F.S. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515: 563-67.
  12. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 2012;12:252-64.
  13. Robert C., Ribas A., Wolchok J.D., Hodi F.S., Hamid O, Kefford R., Weber J.S., Joshua A.M., Hwu W.J., Gangadhar T.C., Patnaik A., Dronca R., Zarour H., Joseph R.W., Boasberg P., Chmielowski B., Mateus C., Postow M.A., Gergich K., Elassaiss-Schaap J., Li X.N., lannone R., Ebbinghaus S.W., Kang S.P., Daud A. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomized dose-comparison cohort of a phase 1 trial, Lancet. 2014;384(9948):1109-17.
  14. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., Wolchok J.D., Hersey P., Joseph R.W., Weber J.S., Dronca R., Gangadhar T.C., Patnaik A., Zarour H., Joshua A.M., Gergich K., Elassaiss-Schaap J., Algazi A., Mateus C., Boasberg P., Tumeh P.C., Chmielowski B., Ebbinghaus S.W., Li X.N., Kang S.P., Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N.Engl. J. Med. 2013;369:134-44.
  15. Robert C., Hamid O., Ribas A., et al. Updated clinical efficacy and safety of MK-3475 (anti-PD-1 monoclonal antibody) in advanced melanoma. Pigment. Cell. Melanoma Res. 2013;26:993(Abstr.).
  16. Ribas A., Puzanov I., et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumabrefractory melanoma (KEYNOTE-002): a randomized, controlled, phase 2 trial. Lancet. Oncol. 2015;16(8):908-18.
  17. Robert C., Schachter J., Long G.V., Arance A., Grob J.J., Mortier L., Daud A., Carlino M.S., McNeil C., Lotem M., Larkin J., Lorigan P., Neyns B., Blank C.U., Hamid O., Mateus C., Shapira-Frommer R., Kosh M., Zhou H., Ibrahim N., Ebbinghaus S., Ribas A. Pembrolizumab versus Ipilimumab in Advanced Melanoma, (KEYNOTE-006). N. Engl J. Med. 2015;372(26):2521-32.
  18. Tsai K.K. Clinical characteristics predictive of response to pembrolizumab in advanced mela noma. ASCO. 2015;9031 Poster Session (Board #274).
  19. Kluger H.M. Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases. ASCO. 2015, Displayed in Poster Session (9009, Board #252).
  20. Kottschade L.A. The use of pembrolizumab for the treatment of metastatic uveal melanoma. ASCO. 2015;(Abstr. 9010).
  21. Le D.T., Uram J.N., Wang H. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N. Engl. J. Med. 2015;372:2509-20.
  22. lams W.T. 2015. PD-1 Inhibition and PD-1 Inhibitors. My Cancer Genome http://www. mycancergenome.org/content/molecular-med-icine/pd-1-inhibition-and-inhibitors/(2015,March 4).
  23. Powles T.,EderJ.P.,FineG.D.,Braiteh F.S.,Loriot Y., Cruz C., Bellmunt J., Burris H.A., Petrylak D.P., Teng S.L., Shen X., Boyd Z., Hegde P.S., Chen D.S., Vogelzang N.J. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature. 2014;515:558-62.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies